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Abstract  
Background: Antihypertensive drugs play a crucial role in reducing cardiovascular morbidity and mortality. 
Variability in prescribing patterns constitutes a major challenge for current healthcare systems. This study aimed 
to compare patterns of use of antihypertensives in general practice in two southern European populations.
Methods: Observational study. Data on antihypertensive drugs consumption in primary care setting (2016) were 
obtained from pharmacy refill records in Campania (Italy) and Aragon (Spain). Prescribing rates and the number 
of defined daily doses [DDD]/1,000 inhabitants/day (DID) were calculated, and the Drug Utilization 90% 
(DU90%) approach used to reveal differences in prescribing patterns in both regions.
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Results: Antihypertensive prescribing rates in Campania and Aragon were 250.8 (95%CI: 250.2-251.3) and 
201.7 (95%CI: 200.9-202.5) users/1,000 inhabitants/year. Overall consumption was of 310.1 and 256.8 DID,
respectively. Spanish users, especially women and the elderly, consumed a greater volume of diuretics.
Conversely, other therapeutic subgroups were more consumed in Campania. However, the most prescribed 
subgroups accounted for comparable proportions of the total consumption in each region.
Conclusions: Both prescribing rates and intensity of antihypertensive use were higher in Campania. Pharmacy 
refill records in cross-national comparisons allow to know the factors influencing variability in prescribing habits 
with a view to improving prescribing quality. 
Key words: Drug utilization study, hypertension, international comparison, pharmacoepidemiology. 
1. Introduction 
Hypertension is a major cardiovascular (CV) risk factor for cardiac, cerebrovascular, and renal diseases and 
death [1]. In European countries, the prevalence of hypertension in the adult population ranges from 30–50%, 
and will likely increase as a consequence of population ageing and current lifestyles [2]. Given their 
demonstrated effects in controlling blood pressure, antihypertensive drugs play a crucial role in reducing CV
morbidity and mortality [3]. However, a recent large international study [4] found that blood pressure was 
uncontrolled in over 50% of individuals receiving antihypertensive treatment. Inappropriate choices of drugs or 
therapeutic regimens may lead to poor patient adherence, consequently contributing to suboptimal disease 
control [5]. Furthermore, even within areas with comparable prevalence of arterial hypertension, prescribed 
treatments can vary widely depending on place of residence [6]. Variability in prescribing patterns and drug 
consumption, and its consequences in terms of effectiveness, safety, equity, and social efficiency of medical 
interventions, thus constitutes a major challenge for current healthcare systems [7]. 
High quality pharmacy claims data, when available and accessible, represents a useful and reliable data source 
for the monitoring of drug utilization at the population level [8]. Moreover, the availability of comparable data 
on drug use across different regions allows cross-national comparisons, which can serve as a stimulus to improve 
the quality of prescribing and to identify target population groups when designing relevant interventions [9,8]. 
In the present study, we used pharmacy claims data from two southern European populations, Campania (Italy) 
and Aragon (Spain). The primary healthcare systems of Spain and Italy share many common features: both are 
predominantly funded with public money, healthcare is managed at the regional government level, and 
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copayment fees apply to similar segments of the respective populations. The health expenditure per capita is 
similar: 2,502 euros in Italy and 2,374 euros in Spain [10]. Citizens covered in both countries are assigned a 
General Practitioner (GP) who is responsible for them and collates a large body of data on each individual 
patient. The duration of a medical consultation in both countries, and consequently the time to examine, listen to, 
and diagnose patients and to recommend pharmacological and/or nonpharmacological treatment, is also similar: 
7 minutes in Spain and 5-7 minutes in Italy. 
This study aimed to compare the patterns of use of antihypertensive drugs in general practice in Campania and 
Aragon. 
2. Patients and methods 
2.1. Study design and data sources 
This observational study examined the pattern of use of antihypertensive drugs in primary care settings in 
Campania (southern Italy) and Aragon (northeastern Spain). Data were obtained from two administrative 
healthcare databases: the Campania Regional Database and the Information System for Medication Consumption 
in Aragon. Drug-utilization data obtained from both these databases have been used in previous studies [11,12].
The Italian database records data on drugs dispensed by community pharmacies in Campania and reimbursed by
the Local Health Authority of Campania Region. The database records the following information for each 
prescription: anonymous patient code; date of dispensation; Anatomical Therapeutic Chemical (ATC) code;
number of Defined Daily Doses (DDD); and number of packages dispensed. This information is matched by 
record-linkage analysis to the civil registry to collect demographic information (i.e., age and sex) on all residents 
recorded in the database. Permission to use this information for the present study was granted by the relevant 
authority. The Spanish database records information on all drugs prescribed using an official medical 
prescription and purchased at pharmacies in Aragon under the coverage of the Aragon Health Service. Each 
entry in the database corresponds to one prescription and includes the following information: anonymous patient 
code; sex; date of birth; date of dispensation; ATC code; number of DDDs; and number of packages dispensed. 
Access to this information was granted by the Aragon Health Sciences Institute. Neither of the two databases 
include information on prescriptions provided by private practices, in-hospital consumption, or drugs purchased 
without a prescription.
2.2. Study populations 
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The study populations consisted of all individuals in the respective regions covered by the corresponding public 
health systems, representing about 99% of the inhabitants. The Italian population studied corresponded to 
individuals living in four Local Health Units in the region of Campania, and accounts for 
60% of the total population of Campania (hereinafter referred to as Campania). On January 1, 2016, the 
populations of Campania and Aragon were approximately 3.4 million and 1.3 million people, respectively. . We 
included all individuals from these populations who were prescribed and subsequently filled a prescription for at 
least one antihypertensive drug during 2016. 
2.3. Drug exposure measurement 
Drugs were identified according to the ATC/DDD system [13] developed by the World Health Organization 
(2018). Drugs included in the present study were those indicated in current European guidelines [14] for the 
initiation and maintenance of antihypertensive treatment: diuretics (thiazides [C03A], chlorthalidone 
[C03BA04], and indapamide [C03BA11]); beta-blockers (C07); calcium antagonists (C08); drugs affecting the 
renin-angiotensin system (including angiotensin-converting-enzyme [ACE] inhibitors [C09A, C09B] and 
angiotensin receptor blockers [C09C, C09D]). It should be noted that the public health services of both regions 
reimburse the cost of all antihypertensive drugs (i.e., the proportion of drugs analyzed with respect to the total 
consumed should be almost 100%).
Following the economic crisis, a copayment for medication prescriptions was instituted in Spain: since 2012, 
pensioners are required to pay a 10% copayment, with a specific limit dependent on their incomes, while 
copayments for those under 65 years of age are established according to three income-tested levels. Exemptions 
are available for the long-term unemployed and for non-contributory pensioners. A copayment system has also 
been implemented for medicines in Italy. In the Campania region a fixed copayment was implemented in 2009 in 
order to limit public spending and improve the appropriateness of drug prescription. Exemptions are applied to 
those of over 65 years of age, as well as low-income groups, pregnant women, and those with severe disabilities 
or specific medical conditions. 
2.4. Data analysis 
Baseline characteristics of both populations were analysed and compared. The utilization of antihypertensive 
drugs was determined by estimating prescribing rates and the intensity of drug use, and by characterizing the
specific medications prescribed. The total prescribing rate (number of individuals per 1000 inhabitants who 
received at least one prescription for an antihypertensive drug in one year), both unadjusted and adjusted for age 
using the direct method and the standard European population, were estimated, as well as corresponding 95% 
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confidence intervals (CI). Prescribing rates by age and sex were also determined for both study populations. The 
intensity of drug use or exposure was determined as the number of DID (DDD/1,000 inhabitants/day) by 
pharmacological subgroup, sex, and age group. Finally, an analysis using the drug utilization 90% (DU90%) 
approach of Bergman et al. [15] was performed. This method groups drugs into chemical subgroups, and then 
ranks them according to the number of DID and the number and type of substances comprising the upper 90%. 
For each region, the most prescribed chemical subgroups were identified and compared. 
3. Results 
In 2016, 848,581 individuals in Campania (250.8 per 1,000 inhabitants per year [95%CI: 250.2-251.3]) and 
263,958 individuals in Aragon (201.7 per 1,000 inhabitants per year [95%CI: 200.9-202.5]) were prescribed an 
antihypertensive drug. Adjustment for age using the direct method revealed rates of 192.6 and 130.6 per 1000 
inhabitants per year in Campania in Aragon, respectively. Prescribing rates in both regions increased with age. 
Rates for those over 80 years of age were 802.6 (95%CI: 798.1-807.0) in Campania and 699.2 (95%CI: 694.1-
704.3) in Aragon. Stratification by sex revealed a significantly higher prescribing rate for women (262.4 
[95%CI: 261.7-263.2]) than men (238.4 [95%CI: 237.7-239.1]) in Campania. Sex-related differences were also 
observed in Aragon, where the prescribing rate was 206.9 (95%CI: 205.8-208.0) for women and 196.4 (95%CI: 
195.4-197.5) for men. For all age groups and both sexes, the prescribing rate was significantly higher in 
Campania than Aragon (Figure 1). The results obtained for women in the middle-aged groups were particularly 
striking. For instance, the prescribing rate for women aged 40-59 years was 249.4 (95%CI: 248.1-250.8) in 
Campania versus 122.1 (95%CI: 120.5-123.6) in Aragon. The equivalent rates for women aged 60-79 was 693.9 
(95%CI: 691.0-696.7) in Campania and 496.0 (95%CI: 492.2-499.8) in Aragon.
Table 1 shows the characteristics of the populations in each of the regions studied. In Campania, women 
accounted for 53.8% of those prescribed antihypertensive drugs, while individuals aged >60 years accounted for 
65.5%. In Aragon, 51.8% of antihypertensive drug users were women while 76.3% were aged >60 years. In 
Campania 27.8% of those prescribed antihypertensive drugs received at least 12 packages of medication and the 
average number of packages per user was 16.1. In Aragon 19.7% of users purchased at least 12 packages during 
the study year, and the average number of packages per user was 14.0. In Campania 52.3% of the study 
population were prescribed a single drug during the study period, 32.4% were prescribed two different drugs,
and 15.3% were prescribed three or more. In Aragon, the corresponding percentages were 64.2%, 27.1%, and 
8.7%.
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Overall consumption of antihypertensive drugs was 310.1 DID in Campania and 256.8 DID in Aragon. Sex-
related differences were observed in both Campania (305.9 and 315.0 DID in men and women, respectively) and 
Aragon (258.4 and 254.7 DID in men and women, respectively), as well as a significant increase in drug use 
with increasing age. For example, consumption in the ≥60 years population was >700 DID in Aragon and >900 
DID in Campania.
Analyses of the different therapeutic subgroups of drugs prescribed in the two study regions revealed significant 
overall (Figure 2) and sex- and age-linked (Figures 3 and 4) differences. In Aragon, particularly among women, 
the DID for diuretics (13.7) was significantly higher than that recorded in Campania (1.4). These differences 
were particularly marked among elderly users, with 55.3 (Aragon) and 6.3 (Campania) DID for diuretics in the 
≥80 years age-group. Conversely, in Campania the number of DID for beta-blocking agents was much higher
than in Aragon for all age groups, and especially among women, for whom DID in Campania was more than 
twice that in Aragon. Similarly, the number of DID for calcium channel blockers and agents affecting the renin-
angiotensin system was higher in the Italian population. Thus, for all three drug types (beta-blocking agents, 
calcium channel blockers, and drugs affecting the renin-angiotensin system), the volume prescribed was higher 
in Campania than Aragon for both men and women, and these differences were maintained for all age groups.
Tables 2 and 3 show the most prescribed antihypertensive drugs in Campania and Aragon, as determined using 
the DU90% method. A total of 17 and 19 chemical subgroups were prescribed, respectively, 7 and 8 of which 
accounted for 90% of the total DID. The subgroups accounting for the greatest prescribed volume were ACE 
inhibitors and angiotensin II antagonists (25.4% and 17.2% of the total DID in Campania and 23.8% and 22.8%
in Aragon). Furthermore, angiotensin II antagonists in combination with diuretics and dihydropyridine 
derivatives (mainly amlodipine) accounted for >10% of the total DID in both regions. In Campania, the 
subgroup of beta-blocking agents accounted for 11.1% of total DID.
4. Discussion 
The present study reveals striking differences in the use of antihypertensive drugs in two southern European 
populations. The proportion of the study population that was prescribed antihypertensive drugs (all age groups 
and both sexes) and the total volume consumed were higher in Campania (Italy) than Aragon (Spain).
Differences in the antihypertensive drug subtypes prescribed were also observed. Below, we discuss some of the 
factors that may contribute to the observed differences.  
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First, it is important to consider certain aspects of the healthcare systems of the study populations that 
significantly influence prescribing habits. Although both the Spanish and Italian National Health Services 
automatically extend coverage to all citizens, regional inequalities in health system performance have been 
described in Italy, where access to healthcare varies largely by region and income group [10]. For example,
healthcare spending in Campania, like most of southern Italy, is below the national average. This gives rise to 
variation in available resources and perceived quality of care and in the prevalence of certain chronic conditions. 
Conversely, the region of Aragon scores around average for most healthcare quality indicators calculated for all 
Spanish Autonomous Communities [10]. Consequently, the comprehensive healthcare provided to chronic 
patients in Campania may suffer from certain limitations [16] compared with that of Aragon, thereby affecting 
the decision to treat and/or the choice of antihypertensive drug.  
The observed discrepancies may also be explained by unequal distribution of hypertension in the two 
populations. According to previous studies, the prevalence of hypertension in Spanish and Italian adult 
populations does not appear to differ markedly, at around 50% in men and slightly less than 40% in women in 
both countries [17,18]. Moreover, the level of awareness of hypertension in both populations is relatively low 
[9,19]. However, it could be possible that the results obtained in Aragon and Campania were not exactly 
comparable to the overall numbers in Spain and Italy, respectively. The lack of clinical information represents, 
thus, a limitation in the interpretation of differences observed in drug prescribing.  
Differences in the prevalence of other CV risk factors or diseases in both populations may also have influenced
the respective prescribing patterns of antihypertensive drugs. The latest Country Health Profile reports [10],
completed by the Organisation for Economic Co-operation and Development (OECD) and the European 
Observatory on Health Systems and Policies, report comparable prevalence of diabetes, smoking, and obesity in 
Italy and Spain. Both are developed southern European regions and the corresponding populations are 
traditionally considered at low risk of CV diseases. Furthermore, given that the respective national 
recommendations are based on the same European guidelines [14], the definition of hypertension, treatment 
goals in the elderly, and choice of hypertensive drug should not differ greatly. These similarities, together with 
policies established in recent years in both countries to create a healthy environment, raise awareness of the 
disease and promote healthy behaviors in the population [14].
Both study populations are ageing and include a large proportion of elderly individuals (in 2016, individuals 
aged ≥65 years accounted for 21% and 18% of the populations of Aragon and Campania, respectively, while 
those ≥80 years accounted for 8% and 5%, respectively). In the present study, stratification of antihypertensive 
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users by age revealed that individuals aged ≥80 years represented a larger proportion of the study population in 
Aragon (26.8%) than Campania (14.8%), while those aged <60 years accounted for a much lower proportion in 
Aragon (23.7%) than Campania (34.5%). Contrary to expectations, these demographic discrepancies did not 
influence antihypertensive prescribing rates, and unadjusted and age-adjusted rates were higher in Campania 
than Aragon.  
Significant differences in total consumption were observed (310.1 DID in Campania versus 256.7 DID in 
Aragon).
Two previous studies of hypertension control in the general populations of Italy [9] and Spain [19] revealed 
marked differences between the two populations in the percentage of treated hypertensive patients with 
controlled blood pressure (57.6% in Italy [2013-14] versus 42.9% in Spain [2008-2010]). A priori, this better 
disease control in Campania could be considered a consequence of the greater intensity of antihypertensive drug 
use observed in our study. However, differences in the period analyzed, the data sources used, and the general 
methodology applied in the Spanish and the Italian studies make the results not comparable. On the other hand, a 
greater intensity of drug use does not always correlate with improved disease control in the population. Drug 
effectiveness is significantly influenced by patient adherence and persistence [20]. Previous studies conducted in 
both populations [11,21] have revealed suboptimal patient persistence for drugs other than antihypertensives, 
suggesting that persistence with antihypertensive drugs may also be suboptimal.  
Differences in consumption were found, with much higher DID values recorded for calcium-channels blockers, 
beta-blocking agents, and drugs affecting the renin-angiotensin system in Campania. European guidelines do not 
recommend a specific initial therapy for hypertension, while others such as the National Institute for Health and 
Care Excellence (NICE) guidelines for hypertension in adults [22] recommend initiating treatment with drugs 
that target the renin-angiotensin system (mainly ACE inhibitors). Given the risk of possible adverse effects, beta-
blocking agents are not recommended as an initial therapy for hypertension by either the NICE or the Spanish 
Society of Family and Community Practice [23]. However, the former recognizes that their use should be 
considered in younger patients and those with certain comorbidities, particularly those for whom agents acting 
on the renin-angiotensin-system are contraindicated, women of child-bearing age, and those with evidence of 
increased sympathetic drive [22]. In this context, the significant differences in the consumption of beta-blocking 
agents observed between our study populations are difficult to explain. Given that the characteristics of the two 
populations appear to differ little, the increased consumption in the Italian population may be the result of 
traditional prescribing habits. For diuretics, the number of DID was greater in Aragon than Campania. Until 
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recently, diuretics were considered the first choice of drug for initiation of antihypertensive treatment [14]. 
However, current guidelines mainly focus on their use in combination with other antihypertensives. The use of 
diuretics in Campania has decreased markedly over the last few years, while in Spain the number of DID for 
diuretics has remained unchanged [24]. The high rate of prescription of these drugs in Aragon therefore appears 
to be related to prescribing habits.  
Despite the observed differences in drug consumption by subgroup, the DU90% method revealed that each of the 
four chemical subgroups studied accounted for similar percentages of the total DID in both populations. 
Similarly, ACE inhibitors alone and angiotensin receptor blockers alone were the two most consumed subgroups 
in each region.
Current European guidelines also make no recommendations as to whether patients should begin treatment with 
monotherapy or a drug combination [14]. An obvious advantage of monotherapy is that effectiveness and 
adverse effects can be ascribed to a single agent. However, in cases of ineffective or poorly tolerated 
monotherapy it can be difficult to find an alternative and patient adherence can be negatively affected.
Combination therapy is associated with earlier and more effective blood pressure reduction and a reduced 
incidence of adverse effects, and is therefore potentially more beneficial in high-risk and less adherent patients 
[6]. The choice between these two approaches will depend on the patient’s clinical status and other diagnoses, 
information not recorded in the data sources used in the present study. Moreover, local guidelines for treatment 
of hypertension may differ slightly from European guidelines, thereby influencing patterns of drug use. It is also 
possible that some drugs classified in the present study as a single active principle could correspond to 
combinations of several drugs (e.g., the ATC code C09BA02 corresponds to the combination of enalapril + 
diuretics). The appropriateness of the drug types prescribed in each region was not assessed in the present study, 
but warrants further research. 
4.1. Strengths and limitations of the study 
To our knowledge, this is the first study to compare the prescribing patterns of antihypertensive drugs in primary 
care settings in two European countries. Up to now, it was difficult to perform such an analysis because 
comparable sources of information were either unavailable or inaccessible. Our study was conducted using two 
administrative pharmacy claim databases of recognized validity and high quality of registration. These databases 
constitute invaluable sources of information for drug-utilization research and analyses of the effects of drugs in 
large populations [25]. Despite these strengths, several considerations or limitations of our study should be 
noted. First, only outpatient consumption that was covered by the public health services was analyzed. 
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Therefore, no data relating to consumption funded by other administrative/funding entities (e.g., prescriptions 
provided by private healthcare providers) or to drugs acquired without prescription were included in the analysis.
However, these categories do not appear to account for a large proportion of prescriptions: for the majority of 
residents in Spain and Italy purchases of prescription drugs, especially those for chronic conditions, are covered 
by the respective public health systems. Second, although the terms “consumption” and “prescribing” are used 
throughout this paper, in reality the data analyzed pertain to drugs that are both prescribed and filled. Third, no
clinical information was recorded in the data sources used for our analysis. The availability of such data would 
allow, for instance, exclusion of drugs prescribed for indications other than hypertension (e.g., beta blockers 
prescribed for ischemic heart disease or cardiac arrhythmia). However, given that pharmacological subgroups 
with a main indication other than arterial hypertension were excluded from our analysis, it is unlikely that this 
category accounts for a large proportion of the prescriptions analyzed. Furthermore, the availability of 
information on clinical status, comorbidities, and other CV risk factors for the study populations could allow 
analysis of the appropriateness of prescribing based on current recommendations. Finally, owing to the cross-
sectional design of the study it was not possible to distinguish between incident and prevalent cases of 
hypertension. Assessment of the intensity of use as well as the type of substance used by stratifying patients 
according to the treatment start date could facilitate interpretation of the differences and similarities observed
between study populations.
4.2. Clinical implications 
The intensity of antihypertensive drug use observed in the two study populations is remarkable considering that 
both Spain and Italy are traditionally considered to have a low risk of CV disease. The marked variability in 
prescribing patterns between Campania and Aragon may be attributable to the unequal distribution of certain 
healthcare resources, differences in the prevalence of behavioral risk factors for CV disease, price differences for 
the same drugs, and prescribing habits, all of which play important roles in determining the choice of 
antihypertensive therapy. Another important factor is the marketing policies used by the pharmaceutical industry, 
primarily to target GPs. Indeed, up to several years ago pharmaceutical companies were one of the main sources 
of information for GPs in both countries [26,27].
Our findings underscore the importance of promoting safe and effective practices when managing hypertensive 
patients. Prescribing decisions should be made in accordance with evidence-based recommendations, 
considering the patient’s situation and preferences. To this end, effective disease management could be achieved 
by adopting a multidisciplinary approach, whereby a range of healthcare providers, as well as the patients 
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themselves, collaborate in the process of CV disease prevention, treatment, and control. Distribution of resources 
according to the needs of the population is essential, as this helps to increase accountability and improve quality 
of care and patient health status, thereby reducing health inequalities [10].
5. Conclusions 
There exist differences in the pattern of use of antihypertensive drugs in the two Southern European populations 
studied. They affect not only to the intensity of use but also to the type of substances utilized.   
The variability found with regards to the pattern of use may be attributed to modifiable behaviors or actions, 
since they both are regions traditionally classified as low-risk for CV diseases. Urgent measures should be taken 
based on evidence-based recommendations, such as those contained in current clinical guidelines, consider the 
patient’s perspective, and always be focused on a multidisciplinary approach.
Key issues 
? Both the proportion of subjects treated, in all age groups and both sexes, and the total volume of 
antihypertensives consumed are higher in Campania (Italy) compared with Aragon (Spain).  
? Calcium channel blockers, agents acting on the renin-angiotensin system and, especially, beta-blocking 
agents, were more consumed in Campania. On the contrary, users in Aragon, especially women and the 
elderly, consumed diuretics to a larger extent, compared with the Italian region. 
? Pharmacy claims databases allow the performance of cross-national comparisons which may represent a 
stimulus to improve the quality of drug utilization 
? Understanding the reasons of the variability found is needed. Meanwhile, the process of prevention-
treatment-control of CV disease should be addressed from a multidisciplinary approach that involves a 
variety of figures, including the patient him/herself. 
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Table legends 
Table 1. Sex and age distribution of the two study populations: individuals treated with antihypertensive drugs 
in 2016. 
Table 2. Ranking of antihypertensive drugs accounting for 90% of total Defined Daily Doses (DDDs) prescribed 
in Campania in 2016.
ATC: Anatomical Therapeutic Chemical; DID: DDD/1,000 inhabitants/day; ACE: angiotensin-converting-
enzyme.
Table 3. Ranking of antihypertensive drugs accounting for 90% of total Defined Daily Doses (DDDs) prescribed 
in Aragon in 2016.
ATC: Anatomical Therapeutic Chemical; DID: DDD/1,000 inhabitants/day; ACE: angiotensin-converting-
enzyme.
Figure captions  
Figure 1. Prescribing rates (number of individuals who received one or more prescriptions per 1000 inhabitants)
for antihypertensive drugs in Campania and Aragon in 2016, stratified by sex and age group.
Figure 2. Comparison of the number of Defined Daily Doses/ 1,000 Inhabitants/Day (DID) for the different 
therapeutic subgroups, 2016. 
Figure 3. Antihypertensive drug consumption in Campania and Aragon. Data are expressed as the number of 
Defined Daily Doses/ 1,000 Inhabitants/Day (DID) in 2016 for each therapeutic subgroup, stratified by age 
group. Note that the scale in the x-axis differs for each age subgroup. 
Figure 4. Antihypertensive drug consumption in 2016 in Campania and Aragon, stratified by sex. Data are 
expressed as the number of Defined Daily Doses/ 1,000 Inhabitants/Day (DID). 
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Table 1. Sex and age distribution of the two study populations: individuals treated with antihypertensive drugs 
in 2016. 
Campania Aragon
Total number of antihypertensive 
drug users
848,581 263,958
Sex 
Women, n (%) 456,117 (53.8%) 136,820 (51.8%)
Men, n (%) 392,464 (46.2%) 127,138 (48.2%)
Age
<40 years old 26,130 (3.1%) 4,924 (1.9%)
40-59 years old 266,817 (31.4%) 57,535 (21.8%)
60-79 years old 430,455 (50.7%) 130,635 (49.5%)
≥80 years old 125,179 (14.8%) 70,864 (26.8%)
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Table 2. Ranking of antihypertensive drugs accounting for 90% of total DDDs prescribed in Campania in 2016.
Rank ATC 
code
Chemical subgroup DID DID 
%
Cumulative 
%
1 C09AA ACE inhibitors, alone 78.8 25.4 25.4
2 C09CA Angiotensin II antagonists, alone 53.3 17.2 42.6
3 C08CA Dihydropyridine derivatives 44.3 14.3 56.9
4 C09DA Angiotensin II antagonists + diuretics 40.2 13.0 69.9
5 C07AB Beta blocking agents, selective 34.4 11.1 80.9
6 C09BA ACE inhibitors + diuretics 22.6 7.3 88.2
7 C09BB ACE inhibitors + calcium channel blockers 10.4 3.4 91.6
8-17 Others 26.0 8.4 100.0
Total 310.1 100.0
ATC: Anatomical Therapeutic Chemical; DID: DDD/1,000 inhabitants/day; ACE: angiotensin-converting-
enzyme.
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Table 3. Ranking of antihypertensive drugs accounting for 90% of total DDDs prescribed in Aragon in 2016.
Rank ATC 
code
Chemical subgroup DID DID 
%
Cumulative 
%
1 C09AA ACE inhibitors, alone 61.1 23.8 23.8
2 C09CA Angiotensin II antagonists, alone 58.6 22.8 46.7
3 C09DA Angiotensin II antagonists + diuretics 33.9 13.2 60.0
4 C08CA Dihydropyridine derivatives 32.2 12.6 72.4
5 C07AB Beta blocking agents, selective 15.9 6.2 78.6
6 C09BA ACE inhibitors + diuretics 15.0 5.8 84.4
7 C03BA Sulfonamides, alone 8.3 3.2 87.7
8 C09DX Angiotensin II antagonists, other 
combinations
6.7 2.6 90.3
9-19 Others 24.9 9.7 100.0
Total 256.7 100.0
ATC: Anatomical Therapeutic Chemical; DID: DDD/1,000 inhabitants/day; ACE: angiotensin-converting-
enzyme.
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